甲状旁腺功能减退：度伐利尤单抗治疗的一种罕见不良反应。
Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab.
作者信息
Kreze Alexander, Homer Matěj, Barešová Tereza, Klemperová Kristina
机构信息
Endocrine Clinic of Internal Medicine Department, The Bulovka University Hospital, Praha, Czech Republic.
Department of Internal Medicine, The Bulovka University Hospital, Praha, Czech Republic.
出版信息
Endocr Oncol. 2022 Sep 22;2(1):K21-K24. doi: 10.1530/EO-22-0047. eCollection 2022 Jan.
SUMMARY
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies approved for the treatment of numerous cancer types. Toxicities induced by ICIs may affect any organ system and manifest as endocrinopathy. The main side effects related to treatment are immune-related adverse events (irAEs), especially thyroid dysfunction and hypophysitis. Rare endocrine irAEs are diabetes insipidus, hypoparathyroidism, thyrotoxic crisis and hypogonadism. We report a case of hypoparathyroidism induced by ICI treatment with durvalumab, which has not previously been described.
LEARNING POINTS
Treatment with immune checkpoint inhibitors (ICIs) is associated with many endocrine side effects.It is recommended that patients treated with ICIs are observed by an endocrinologist.If side effects are treated accordingly, ICI therapy can continue.
摘要
免疫检查点抑制剂（ICIs）是被批准用于治疗多种癌症类型的单克隆抗体。ICIs诱导的毒性可能影响任何器官系统，并表现为内分泌病。与治疗相关的主要副作用是免疫相关不良事件（irAEs），尤其是甲状腺功能障碍和垂体炎。罕见的内分泌irAEs包括尿崩症、甲状旁腺功能减退、甲状腺毒症危象和性腺功能减退。我们报告了一例由度伐利尤单抗ICI治疗引起的甲状旁腺功能减退病例，此前尚未有过相关描述。
学习要点
免疫检查点抑制剂（ICIs）治疗与许多内分泌副作用相关。建议由内分泌科医生对接受ICIs治疗的患者进行观察。如果相应地治疗副作用，ICI治疗可以继续。
Zotero 插件